Advertisement

GENLEAP Bags Rs 27 Cr In Pre-series A Round

GENLEAP is extending its footprint both geographically and in terms of products launches,providing DNA-led solutions for personal career growth and development, health and wellness, relationship compatibility, disease susceptibility and more

The DNA-based self-discovery and career life cycle management platform from India GENLEAP has announced the successful conclusion of its pre-series A funding of 27 crores ($3.3 million). This round follows the earlier Rs 60 Crores ($7.4 million) seed round raised in 2021.

The fundraise includes several existing investors, including Mike Holland (former CEO of Embassy REIT), Sanjay Dutt (CEO and MD, Tata Realty and infrastructure), Neeraj Bansal(Co-head and COO – India Global with a Big Four Consulting Firm), Karthikeyan Balasubramanian, Deepak Kaul and Manish Dhawan (Olam Food International), and new investors like Vikaash Khdloya (ex-Private equity professional) Sunil Bajaj (Partner with a leading multinational, multi-disciplinary consulting firm),Yoguen Oukabay, Mandeep Mehta (Group CFO with Policy Bazaar) in their personal capacities. 

GENLEAP is also extending its footprint both geographically and in terms of products launches,providing DNA-led solutions for personal career growth and development, health and wellness, relationship compatibility, disease susceptibility and more.

The proceeds from this fundraise, and IPO would be used to further expand its marketing and distribution footprint globally, including entry into the US, middle east, and European markets.

GENLEAP commenced operations in 2021, offering DNA-led self-discovery and career lifecycle management to its aspirants, including students and working professionals.

On the announcement of the closure of this funding round, the Founder and CEO of GENLEAP, Sachin Sandhir, said, “GENLEAP will soon be expanding its geographical footprint and growth in the US, Middle east and other markets and given its global ambitions to become a leading force in the Genomics testing and solutions market, a $90 billion industry. GENLEAP AI, the US entity of GENLEAP, would now be listed in the Regulation A plus market and will launch a 50 million dollar IPO in the US market shortly."

Mandeep Mehta, Group CFO, Policy Bazaar, said, “GENLEAP provides the most powerful end-to-end career lifecycle management platform in today’s market. Its innovative approach helps one discover the hidden talents and innate personality traits to find how one’s environment and life experiences are helping in realizing this potential; and what’s missing.”


Tags assigned to this article:
investment startup GenLeap

Around The World

Advertisement